TY - JOUR
T1 - Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior
AU - Butini, Stefania
AU - Gemma, Sandra
AU - Campiani, Giuseppe
AU - Franceschini, Silvia
AU - Trotta, Francesco
AU - Borriello, Marianna
AU - Ceres, Nicoletta
AU - Ros, Sindu
AU - Coccone, Salvatore Sanna
AU - Bernetti, Matteo
AU - De Angelis, Meri
AU - Brindisi, Margherita
AU - Nacci, Vito
AU - Fiorini, Isabella
AU - Novellino, Ettore
AU - Cagnotto, Alfredo
AU - Mennini, Tiziana
AU - Sandager-Nielsen, Karin
AU - Andreasen, Jesper Tobias
AU - Scheel-Kruger, Jorgen
AU - Mikkelsen, Jens D
AU - Fattorusso, Caterina
N1 - Keywords: Animals; Antipsychotic Agents; Behavior, Animal; Binding Sites; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Molecular; Molecular Structure; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship
PY - 2009
Y1 - 2009
N2 - Dopamine D(3) antagonism combined with serotonin 5-HT(1A) and 5-HT(2A) receptor occupancy may represent a novel paradigm for developing innovative antipsychotics. The unique pharmacological features of 5i are a high affinity for dopamine D(3), serotonin 5-HT(1A) and 5-HT(2A) receptors, together with a low affinity for dopamine D(2) receptors (to minimize extrapyramidal side effects), serotonin 5-HT(2C) receptors (to reduce the risk of obesity under chronic treatment), and for hERG channels (to reduce incidence of torsade des pointes). Pharmacological and biochemical data, including specific c-fos expression in mesocorticolimbic areas, confirmed an atypical antipsychotic profile of 5i in vivo, characterized by the absence of catalepsy at antipsychotic dose.
AB - Dopamine D(3) antagonism combined with serotonin 5-HT(1A) and 5-HT(2A) receptor occupancy may represent a novel paradigm for developing innovative antipsychotics. The unique pharmacological features of 5i are a high affinity for dopamine D(3), serotonin 5-HT(1A) and 5-HT(2A) receptors, together with a low affinity for dopamine D(2) receptors (to minimize extrapyramidal side effects), serotonin 5-HT(2C) receptors (to reduce the risk of obesity under chronic treatment), and for hERG channels (to reduce incidence of torsade des pointes). Pharmacological and biochemical data, including specific c-fos expression in mesocorticolimbic areas, confirmed an atypical antipsychotic profile of 5i in vivo, characterized by the absence of catalepsy at antipsychotic dose.
U2 - 10.1021/jm800689g
DO - 10.1021/jm800689g
M3 - Journal article
C2 - 19072656
SN - 0022-2623
VL - 52
SP - 151
EP - 169
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 1
ER -